Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

NCT03991403 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

228

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Atezolizumab(Tecentriq)
DRUG: Pemetrexed
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Carboplatin or cisplatin

Sponsor

Samsung Medical Center